Genfit S.A. (NASDAQ:GNFT) Short Interest Update

Genfit S.A. (NASDAQ:GNFT) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 96,300 shares, a growth of 7.2% from the May 31st total of 89,800 shares. Based on an average trading volume of 22,100 shares, the short-interest ratio is presently 4.4 days. Approximately 0.2% of the shares of the company are short sold.

Institutional Investors Weigh In On Genfit

A hedge fund recently raised its stake in Genfit stock. Optiver Holding B.V. boosted its holdings in shares of Genfit S.A. (NASDAQ:GNFT) by 2,229.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 82,359 shares of the company’s stock after purchasing an additional 78,823 shares during the quarter. Optiver Holding B.V. owned about 0.17% of Genfit worth $315,000 at the end of the most recent quarter. 2.24% of the stock is owned by institutional investors and hedge funds.

Genfit Price Performance

NASDAQ:GNFT opened at $3.98 on Thursday. Genfit has a 1 year low of $2.89 and a 1 year high of $6.05. The company has a current ratio of 2.94, a quick ratio of 2.94 and a debt-to-equity ratio of 0.92. The firm’s fifty day simple moving average is $4.22 and its 200 day simple moving average is $3.87.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of Genfit in a research report on Thursday, June 6th.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.